Edwards Lifesciences (EW) Operating Leases (2019 - 2026)

Edwards Lifesciences has reported Operating Leases for 8 years, with the latest figure at $80.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 2.82% year-over-year to $80.1 million; the trailing twelve-month figure through Mar 2026 stood at $80.1 million (up 2.82% YoY), and the FY2025 full-year result was $82.6 million, up 4.69% from the prior year.
• Operating Leases for Q1 2026 stood at $80.1 million, down from $82.6 million in the prior quarter.
• The five-year high for Operating Leases was $95.0 million in Q4 2022, with the low at $63.5 million in Q2 2022.
• Average Operating Leases over 5 years is $76.0 million, with a median of $77.2 million recorded in 2024.
• Year-over-year, Operating Leases jumped 37.48% in 2022 and retreated 11.41% in 2025.
• Tracing EW's Operating Leases over 5 years: stood at $95.0 million in 2022, then retreated by 7.26% to $88.1 million in 2023, then dropped by 10.44% to $78.9 million in 2024, then increased by 4.69% to $82.6 million in 2025, then slipped by 3.03% to $80.1 million in 2026.
• The last three Operating Leases figures came in at $80.1 million (Q1 2026), $82.6 million (Q4 2025), and $75.3 million (Q3 2025), per Business Quant data.

Peer Comparison